<DOC>
	<DOCNO>NCT02401828</DOCNO>
	<brief_summary>48-week open label randomize phase IV investigator initiate intervention study . The purpose study evaluate whether HIV-1 suppression maintain DTG monotherapy HIV-1 infect , virologically suppressed patient cART . 104 adult fulfil exclusion criterion stable cART randomize 2 investigational arm . The first arm contain direct switch population . This population switch directly stable cART Dolutegravir mono-therapy baseline visit . The second arm contain delayed-switch population . This group switch stable cART Dolutegravir monotherapy 24 week baseline visit . The main goal investigate Dolutegravir mono-therapy could non-inferior cART virological suppress HIV-1 infected adult . If interim analysis ( performed 40 patient dolutegravir monotherapy pass week 12 ) show safe continue study , additional 30 patient include top 104 patient need primary endpoint analysis . In contrast primary endpoint population , additional 30 patient CD4 nadir &lt; 200 CD4 &gt; 350 time screen visit . Besides , 30 patient fulfill exclusion criterion primary endpoint population ( specifically viral load never &gt; 100.000 ) . These 30 patient part pilot study look possibility broaden eligible population future large randomized clinical trial .</brief_summary>
	<brief_title>The Dolutegravir Antiretroviral Mono-Therapy HIV Trial</brief_title>
	<detailed_description>DTG Monotherapy consider non-inferior cART low bound one side 97.5 % CI difference proportion patient reach primary endpoint lower -12 % . For purpose , sample size 52 per arm would provide 80 % power alpha 0.025 establish non-inferiority DTG monotherapy compare cART primary endpoint success rate 95 % treatment arm .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Documented HIV1 positive ELISA Western Blot Plasma HIVRNA &gt; 1000 c/ml . 18 year old . HIVRNA ≤50 copies/mL ≥24 week . Historical baseline HIVRNA plasma load &lt; 100.000 c/ml CD4 count nadir precART ≥200 cells/mm3 Not strong UGT1A1 CYP3A4 induce agent state DTG SPC . General medical condition interfere trial procedure ( investigator ' discretion ) Females plan become pregnant next 18 month baseline visit Females eligible : 1 . They plan become pregnant study 2 . Negative screening pregnancy test use one follow method : 1.Abstinence penile/vaginal intercourse study ; 2.Double barrier contraceptive method 1 must condom . Previous virological failure ART . Patient without document antiHBs antibody . Subjects positive hepatitis B screening ( HBsAg+ ) . Any documented genotypic HIV1 resistance least lowlevel resistance accord stanford HIV drug resistance database No record historical baseline plasma viral load available Subjects concomitant CDCC opportunistic infection within 90 day screen . Subjects history allergy INI . Subjects creatinine clearance &lt; 50mL/min accord CKDEPI . Subjects hepatic impairment least ChildPugh B . Exposure experimental drug experimental HIV1 vaccine within 90 day start DTG . Screening ALT &gt; 5x ULN ALT &gt; 3xULN bilirubin &gt; 2 ULN . Patient ( man woman ) plan hop conceive child/become pregnant study Patients take DTG 2 hour 6 hour antacid , calciumcarbonate iron supplement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>